


JFie



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Suzanne Chamberland *et al.*  
Application No.: 10/567,660

Filed: February 8, 2006

Confirmation No.: 3960

For: HALOGENATED QUINAZOLINYL  
NITROFURANS AS ANTIBACTERIAL  
AGENTS

Examiner: \_\_\_\_\_

Art Unit: \_\_\_\_\_

Attorney Reference No.: 4810-73194-01

MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Name: Debra GordonDate Mailed June 20, 2006TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- Information Disclosure Statement ("IDS")
- Form PTO/SB/08A and copies of twenty-three non-U.S. references cited thereon (together with at least partial English language translations of DE 2,140,280 and BE 672504)

It is believed that no fee is required to file this IDS; however, the Commissioner is hereby authorized to charge any fees that may be required in connection with this filing to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By: Debra Gordon  
Debra A. Gordon, Ph.D.  
Registration No. 54,128



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Suzanne Chamberland *et al.*

Application No.: 10/567,660

Filed: February 8, 2006

Confirmation No.: 3960

For: HALOGENATED QUINAZOLINYL  
NITROFURANS AS ANTIBACTERIAL  
AGENTS

Examiner: \_\_\_\_\_

Art Unit: \_\_\_\_\_

Attorney Reference No.: 4810-73194-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Name: Dawn Andra

Date Mailed June 20, 2006

MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)

Listed on the accompanying form PTO/SB/08A are several English-language and non-English language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

The non-English language documents have been provided with an English abstract (WO 2003/091224) or a complete (DE 2,140,280) or partial (BE 672504) English translation from which the Office can determine the relevance of the documents.

Copies of foreign patents, foreign patent applications, and other non-patent documents accompany this Information Disclosure Statement (“IDS”). Copies of United States patents, United States published patent applications, and unpublished U.S. applications otherwise available on PAIR do not have to be provided (37 C.F.R. 1.98(a)(2)(ii) and Official Gazette Notice on October 19, 2004 (1287 OG 163)). Applicants will provide copies of such U.S. patents or U.S. patent applications upon request.

Applicants filed this IDS before the mailing date of a first Office action on the merits. As a result, no fee should be required for this filing. However, if the Commissioner determines that a fee is required to file this IDS, please charge any such fee to the deposit account referenced on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By: Debra Gordon  
Debra A. Gordon, Ph.D.  
Registration No. 54,128

cc: Docketing


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind code <sup>2</sup> (if known)			
	A1	US-2004/0043987	03-04-2004	Neurosearch A/S	
	A2	US-2004/0131628 A1	07-08-2004	Bratzler, Robert L. et al.	
	A3	US-6,479,499	11-01-2004	National Science Council (TW)	
	A4	US-2003-0125344	07-03-2003	Bayer Corporation	
	A5	US-2003/0220357	11-27-2003	Bankston, D. et al.	
	A6	US-2002161014 A1	10-31-2002	Chanchal, Sadhu et al.	
	A7	US-2002/0025968	02-28-2002	Pamkcu, R.; Piazza, G.	
	A8	US-6,429,311	08-06-2002	Sepracor Inc.	
	A9	US-2001/0018518	08-30-2001	Gao, Yun	
	A10	US-6,306,864	10-23-2001	Pfizer, Inc.	
	A11	US-6,380,204	10-23-2001	Xerox Corporation	
	A12	US-6,184,377 B1	02-06-2001	Sepracor Inc.	
	A13	US-5,436,233	07-25-1995	Ono Pharmaceutical Co. Ltd.	
	A14	US-5,439,895	08-08-1995	Ono Pharmaceutical Co. Ltd.	
	A15	US-3,970,648	07-20-1976	Diamond Shamrock	
	A16	US-3,973,021	08-03-1976	Diamond Shamrock	
	A17	US-3,974,277	08-20-1976	Diamond Shamrock	
	A18	US-3,542,784	11-24-1970	Norwich	
	A19	US-3,324,122	07-06-1967	Norwich	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO 2005/014585 A1	Feb. 17/05	Ulysses Pharmaceuticals Products Inc.		<input type="checkbox"/>
	B2	WO 2004/004658 A2	Jan. 15/04	Point Therapeutics, Inc.		<input type="checkbox"/>
	B3	WO 2003/091224 A1	Nov 6/03	Nippon Shinyaku Co. Ltd.		<input type="checkbox"/>
	B4	WO 01/81346 A3	Nov. 1/01	ICOS Corp.		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds codes of USPTO patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	Not yet assigned
		Filing Date	February 8, 2006
		First Named Inventor	Suzanne Chamberland et al.
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 2	of 3	Attorney Docket Number	4810-73194-01

**Foreign Patent Documents (continued)**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	B5	WO 9834111 A1	Aug. 6/98	Trega Biosciences Inc. (US)		<input type="checkbox"/>
	B6	WO 9834115 A1	Aug. 6/98	Trega Biosciences Inc. (US)		<input type="checkbox"/>
	B7	DE 2,140,280	Feb. 17/72	Chemische Fabrik von Heyden GmbH		<input type="checkbox"/>
	B8	GB 1,168,430	Oct. 22/69	The Norwich Pharmacal Company		<input type="checkbox"/>
	B9	BE 672504	Mar. 16/66	The Norwich Pharmacal Company		<input type="checkbox"/>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city and /or country where published.	T <sup>2</sup>
	C1	Burch, Homer A. "Nitrofuryl heterocycles, IV. 4-Amino-2-(5-nitro-2-furyl) quinazoline derivatives" <i>Journal of Medicinal Chemistry</i> (1966), 9(3), 408-10	<input type="checkbox"/>
	C2	Cohen, Samuel M. et al., "Comparative carcinogenicity of 5-nitrothiophenes and 5-nitrofurans in rats" <i>Journal of the National Cancer Institute</i> (1976), 57(2), 277-82	<input type="checkbox"/>
	C3	Desos, Patrice et al. "Structure-Activity Relationships in a Series of 2[1H]-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7 Dichloro-2[1H]-oxoquinoline-3-phosphonic Acid, a New Potent and Selective AMPA/Kainate Antagonist with Neuroprotective Properties" <i>Journal of Medicinal Chemistry</i> (1996) 39(1) 197-206	<input type="checkbox"/>
	C4	Gupta, K. "Addressing Antibiotic Resistance" <i>Dis. Mon.</i> (2003) 49(2) 99-110	<input type="checkbox"/>
	C5	Hour, Mann-Jen "6-Alkylamino- and 2,3 Dihydro-3'-methoxy-2-phenyl-4-quinazolinones and Related Compounds: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization" <i>Journal of Medicinal Chemistry</i> (2000) 43(23) 4479-4487	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	Not yet assigned
Sheet	3	Filing Date	February 8, 2006
		First Named Inventor	Suzanne Chamberland et al.
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
		Attorney Docket Number	4810-73194-01

<b>NON PATENT LITERATURE DOCUMENTS (continued)</b>				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city and /or country where published.		T <sup>2</sup>
	C6	Jiang, Jack B. et al. "Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization" <i>Journal of Medicinal Chemistry</i> (1990) 33(6) 1721-28		<input type="checkbox"/>
	C7	Molina, Enrique et al., "Designing Antibacterial Compounds through a Topological Substructural Approach" <i>Journal of Chemical Information and Computer Sciences</i> (2004), 44(2), 515-521		<input type="checkbox"/>
	C8	Moskalenko, N. Yu et al., "4-Amino-2-styrylquinazolines,- a new class of antiprotozoal drugs" <i>Khimiko-Farmatsevticheskii Zhurnal</i> (1986), 20(4), 437-46		<input type="checkbox"/>
	C9	Nicolle, L.E. "Urinary Tract Infection: Traditional Pharmacologic Therapies" (2003) 49(2) 111-128		<input type="checkbox"/>
	C10	Ogawa, Nobuo et al. "Synthesis and histamine H2-antagonist activity of 4-quinzolinione derivatives" <i>Chemical &amp; Pharmaceutical Bulletin</i> (1988) 36(8) 2955-67		<input type="checkbox"/>
	C11	Van Natta, J.P. et al., "Determination of untreated whole-milk effects on in vitro antibacterial activity" <i>Applied Microbiology</i> (1970), 19(2), 220-23		<input type="checkbox"/>
	C12	Yakhontov, L.N. et al., "Synthesis and Study of Biological Activity of Substituted 4-Amino-2-Styrylquinazolines" <i>Khimiko-Farmatsevticheskii Zhurnal</i> (1975) 9(11) 12-18		<input type="checkbox"/>
	C13	Zhikhareva, G.P. et al., "Synthesis and Anti-Inflammatory Activity of Substituted 2-styryl-4-(δ-diethylamino-α-methylbutylamino)-6-nitro and 2-styryl-4-(δ-diethylamino-α-methylbutylamino)-6-aminoquinazolines" <i>Khimiko-Farmatsevticheskii Zhurnal</i> (1980) 14(2), 45-49		<input type="checkbox"/>
	C14	Zhikhareva, G.P. et al., "Synthesis and Antiviral Activity of Substituted 4-(δ-diethylamino-α-methylbutylamino)-2-styrylquinazolines" <i>Khimiko-Farmatsevticheskii Zhurnal</i> (1978) 12(11) 44-48		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.